|The following article is part of conference coverage from the 2018 Fall Clinical Dermatology Conference in Las Vegas, Nevada.Dermatology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in dermatology. Check back for the latest news from Fall Clinical Derm 2018.|
Brodalumab has shown efficacy and safety in treating moderate to severe psoriasis in a 2-year study, with over 60% of participants achieving a 100% reduction in psoriasis. This research was presented at the 2018 Fall Clinical Dermatology Conference, held October 18-21, 2018, in Las Vegas, Nevada.
This study included 3625 individuals who were given brodalumab 210 mg to treat psoriasis, of whom 676 completed the maintenance and extension phases. The dose varied in the induction phase, but was ultimately changed to 210 mg once every 2 weeks.
Data were recorded on Psoriasis Area Severity Index (PASI) 100, 90, and 75, as well as static Physician’s Global Assessment (sPGA) scores of 0 or 1 throughout the AMAGINE-2/-3 maintenance and long-term extension phases. A sPGA score of 0 or 1 was achieved and sustained by over 79% of participants. Over 60% achieved PASI 100, and over 90% achieved a PASI 75. These results were sustained between weeks 52 and 108.
Data were also recorded on exposure-adjusted, treatment-emergent adverse events, which included arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, tinea infections, conjunctivitis, and candida infections.
The study researchers concluded that “[brodalumab] demonstrated consistent safety and sustained efficacy for >2 years (108 weeks), with >60% of patients achieving PASI 100 and >79% of patients achieving sPGA 0/1.”
Disclosures: A. Jacobson is an employee of Ortho Dermatologics; R. Pillai is an employee of Dow Pharmaceutical Sciences Inc., and R.J. Israel is an employee of Bausch Health. The study was sponsored by Ortho Dermatologics. For a full list of disclosures, please see the full reference.
For more coverage of Fall Clinical Derm 2018, click here.
Lebwohl M, Papp K, Tyring S, et al. Long-term efficacy of brodalumab for the treatment of moderate-to-severe psoriasis in 2 pivotal phase 3 clinical trials. Presented at: 2018 Fall Clinical Dermatology Conference. October 18-21, 2018; Las Vegas, NV.